AstraZeneca news. Headlines for AZN.

AstraZeneca News

Prices

Results Calendar charts

Charts

Watchlist

Share Tips

Here are all todays headlines related to AstraZeneca News. If you wish to drill deeper to view past AstraZeneca News items, follow the next 20 headlines link at the foot of the page.

Tuesday broker round-up

29-05-2018

Paragon: Numis upgrades to buy with a target price of 452p.

Friday broker round-up

25-05-2018

Royal Mail: Berenberg downgrades to sell with a target price of 460p.

AstraZeneca reaches another milestone with Imfinzi trial

25-05-2018

AstraZeneca, along with its biologics research and development arm MedImmune, announced positive overall survival results for the Phase III PACIFIC trial on Friday.

Tuesday broker round-up

22-05-2018

Entertainment One: Numis upgrades to add with a target price of 340p.

Monday broker round-up

21-05-2018

G4S: Kepler Cheuvreux initiates at buy with at a target price of 310p.

AstraZeneca gets FDA green light for hyperkalaemia drug

21-05-2018

AstraZeneca received US regulatory approval for its Lokelma treatment for high potassium levels in the blood and, separately, submitted a new drug application in Japan for a diabetes treatment.

Friday broker round-up

18-05-2018

Thomas Cook: Numis downgrades to add with a target price of 159p.

AstraZeneca confident of return to growth despite mixed Q1

18-05-2018

AstraZeneca has a tough first quarter as sales and earnings came in lower than expected due to investment in drug launches and a larger erosion of its Crestor statin drug than expected, but there were encouraging performance from newer drugs.

Tuesday broker round-up

15-05-2018

Indivior: Citigroup downgrades to neutral with a target price of 500p.

Market buzz: Severn Trent down and ITV up as analysts opine

11-05-2018

1226: The FTSE 100 is being held down by a stronger pound, down very slightly just past midday. Mike van Dulken, head of research at Accendo Markets, notes that the pound is helping miners while healthcare is under pressure ahead of a President Trump speech on the matter.

AstraZeneca's respiratory biologic drug fails COPD trial

11-05-2018

AstraZeneca's late-stage Galathea trial for its first respiratory biologic drug failed to meet its primary goal in treatment of chronic obstructive pulmonary disease.

AstraZeneca offloads Seroquel rights for $538m, gets Lynparza green light

08-05-2018

AstraZeneca has agreed a $538m deal to license-out the sale of its Seroquel schizophrenia and bipolar treatment and separately has been boosted by an approval of its Lynparza cancer treatment from European regulators.

European regulators give positive opinion to AstraZeneca's Tagrisso

27-04-2018

AstraZeneca said on Friday that European regulators have adopted a positive opinion of its Tagrisso drug and recommended a change to the terms of the marketing authorisation to include the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.

Tuesday broker round-up

24-04-2018

(WebFG News) - BAE Systems: Berenberg upgrades to buy with a target price of 700p.

AstraZeneca 'disappointed' with latest Imfinzi test results

24-04-2018

(WebFG News) - AstraZeneca, alongside its its biologics research and development arm MedImmune, announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had received at least two prior treatments on Tuesday.

FDA gives AstraZeneca's Tagrisso the thumbs up for first-line treatment

19-04-2018

AstraZeneca announced on Thursday that the US Food and Drug Administration has approved Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer, whose tumours have epidermal growth factor receptor mutations as detected by an FDA-approved test.

Tuesday broker round-up

03-04-2018

CMC Markets: Shore Capital Markets upgrades to buy from hold.

AstraZeneca's leukaemia and breast cancer treatments make regulatory progress

03-04-2018

AstraZeneca has reported regulatory progress in the US and Europe for treatments for a rare form of leukaemia and breast cancer.

Jefferies ups AstraZeneca to 'buy', says it's at a 'turning point'

19-03-2018

Jefferies upgraded AstraZeneca to 'buy' from 'hold' on Monday, lifting the price target to 5,600p from 5,075p as it said the pharmaceuticals giant is at a "turning point".

Monday broker round-up

19-03-2018

Close Brothers Group plc: Berenberg downgrades to hold with a target price of 1,530p.

Next 20 headlines >>

Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk

Get a free widget for your website with our latest headlines.

You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.

Visit our widget builder